Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | RXRA | P19793 | 10/20 | 0.39 |
| ▸ | RXRB | P28702 | 10/20 | 0.39 |
| ▸ | RXRG | P48443 | 7/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14797136 | 0.87 | S1PR1 (0.71) | S1PR1CETP | |
| SCHEMBL2273845 | 0.85 | S1PR1 (0.70) | S1PR1RXRARXRBRXRG | |
| SCHEMBL14797108 | 0.85 | S1PR1 (0.70) | S1PR1 | |
| SCHEMBL2225216 | 0.85 | S1PR1 (0.69) | S1PR1CETP | |
| SCHEMBL14797000 | 0.84 | S1PR1 (0.74) | S1PR1MRGPRX4CETP | |
| SCHEMBL14797016 | 0.84 | S1PR1 (0.73) | S1PR1CETP | |
| SCHEMBL14797014 | 0.84 | S1PR1 (0.68) | S1PR1CETP | |
| SCHEMBL14797076 | 0.83 | S1PR1 (0.72) | S1PR1CETP | |
| SCHEMBL2223368 | 0.83 | S1PR1 (0.83) | S1PR1CETP | |
| SCHEMBL14797212 | 0.82 | S1PR1 (0.66) | S1PR1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| EP-2523962-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086079-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, EDNRA, EDF1 | S1PR1 129/4885RXRA 1160/4885RXRB 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.